Howard Hughes Medical Institute is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Location | Chevy Chase, MD, USA |
|---|---|
| Type | Private Medical Research Institute |
| Founded | 1953 |
| Founder | Howard Hughes |
| Website | [hhmi.org](https://www.hhmi.org/) |
The Howard Hughes Medical Institute (HHMI) is a leading nonprofit medical research organization dedicated to advancing biomedical research and science education. Founded in 1953 by aviator and industrialist Howard Hughes, HHMI invests over $700 million annually in research, primarily through its investigator program that supports approximately 250 HHMI Investigators across the United States.
HHMI has been instrumental in advancing our understanding of neurodegenerative diseases, funding researchers who have made groundbreaking discoveries in Alzheimer's disease, Parkinson's disease, ALS, and other conditions.
HHMI Investigators are among the most accomplished scientists in their fields, selected through a rigorous competitive process. Many HHMI Investigators focus on neurodegenerative disease research:
HHMI's Janelia Research Campus in Ashburn, Virginia, provides an innovative environment for scientific discovery:
| Investigator | Institution | Research Focus |
|---|---|---|
| Dr. Thomas Südhof | Stanford | Synaptic transmission, Alzheimer's disease |
| Dr. Michael Goedert | MRC LMB Cambridge | Tau, alpha-synuclein, prion diseases |
| Dr. James Rothman | Yale | Synaptic vesicle trafficking |
| Dr. Richard Roberts | USC | RNA processing, ALS |
| Dr. Susan Lindquist | MIT/HHMI | Protein folding, prions, neurodegeneration |
| Dr. Huda Zoghbi | Baylor/HHMI | Rett syndrome, neurological disorders |
| Disease Area | HHMI Research Contributions |
|---|---|
| Alzheimer's Disease | Amyloid processing, tau propagation, synaptic failure |
| Parkinson's Disease | Alpha-synuclein biology, LRRK2 function, mitochondrial quality control |
| ALS/FTD | TDP-43 proteinopathy, C9orf72 mechanisms, RNA metabolism |
| Prion Diseases | Prion protein structure, strain diversity, therapeutic approaches |
| Huntington's Disease | Mutant huntingtin function, therapeutic target identification |
HHMI collaborates with:
HHMI supports training through:
The study of Howard Hughes Medical Institute has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Goedert M, et al. (1988). "Formation of neuronal inclusions in the brains of patients with Alzheimer's disease and with experimental animals." Annals of the New York Academy of Sciences. PMID:2904669.
Spillantini MG, et al. (1997). "Alpha-synuclein in Lewy bodies." Nature. PMID:9213294.
Südhof TC, et al. (2013). "Synaptic neurotransmitter release by SNARE complexes." Cold Spring Harbor Perspectives in Biology. PMID:23580979.